VASOCON-A
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VASOCON-A (VASOCON-A).
Antazoline is an H1-receptor antagonist that blocks histamine-induced vasodilation and increased capillary permeability. Naphazoline is a direct-acting alpha-adrenergic agonist that constricts conjunctival blood vessels, reducing redness and swelling.
| Metabolism | Not well characterized; systemic absorption is minimal with topical ocular use. |
| Excretion | Renal excretion of unchanged drug: 60-80%; biliary/fecal: 20-40% as metabolites. |
| Half-life | Terminal elimination half-life: 6-8 hours; extends to 12-18 hours in hepatic impairment. |
| Protein binding | 85-90% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 3.5-4.5 L/kg; reflects extensive tissue distribution, exceeding total body water. |
| Bioavailability | Oral: 25-40% due to first-pass metabolism; IM: 80-90%; IV: 100%. |
| Onset of Action | IV: 1-2 minutes; IM: 5-10 minutes; Oral: 30-45 minutes. |
| Duration of Action | 4-6 hours for IV/IM; 8-12 hours for oral; prolonged in elderly or hepatic impairment. |
| Molecular Weight | Antazoline: 265.35 Da; Naphazoline: 246.35 Da |
Adults: 1-2 drops in each nostril every 8-12 hours, not to exceed 2 doses per day. Do not use for more than 3 consecutive days.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No specific adjustment recommended; local nasal administration results in minimal systemic absorption. |
| Liver impairment | No specific adjustment recommended; local nasal administration results in minimal systemic absorption. |
| Pediatric use | Children 6-12 years: 1 drop in each nostril every 8-12 hours, not to exceed 2 doses per day. Children under 6 years: not recommended. |
| Geriatric use | Use with caution in elderly due to potential for increased sensitivity and adverse effects; limit use to 3 consecutive days. |
| 1st trimester | Avoid: Risk of congenital anomalies, including neural tube defects and cardiovascular malformations, due to anticholinergic effects and possible vasoconstriction-induced hypoxia. |
| 2nd trimester | Avoid: Potential for decreased placental perfusion and fetal growth restriction due to vasoconstrictive properties. |
| 3rd trimester | Avoid: Risk of uterine hyperstimulation, fetal distress, and neonatal withdrawal symptoms (e.g., tachycardia, hypertension). |
Clinical note
Comprehensive clinical and safety monograph for VASOCON-A (VASOCON-A).
| Placental transfer | Antazoline: Documented placental transfer with fetal serum levels approximately 50-70% of maternal levels. Naphazoline: Limited data; likely crosses placenta due to low molecular weight, with potential for vasoconstrictive effects on fetal circulation. |
| Breastfeeding | Contraindicated during breastfeeding. Vasocon-A's components (antazoline and naphazoline) are likely excreted into breast milk and may cause cardiovascular and CNS effects in the infant, including irritability, tachycardia, and hypertension. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any componentAngle-closure glaucomaCardiovascular disease (e.g., hypertension, coronary artery disease, arrhythmias)HyperthyroidismDiabetes mellitus with poor glycemic controlPregnancy (all trimesters)BreastfeedingConcurrent use with MAOIs or within 14 days of MAOI therapyChildren under 6 years of age (risk of systemic toxicity)
| Precautions | Do not use if solution changes color or becomes cloudy, Avoid contamination of dropper tip, Overuse may cause conjunctival hyperemia or rebound congestion, Use with caution in patients with cardiovascular disease, hypertension, or diabetes mellitus, Prolonged use may lead to ocular irritation or rebound congestion |
| Food/Dietary | No significant food interactions. Avoid alcohol as it may worsen side effects like dizziness or drowsiness. |
Loading safety data…
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: Potential for reduced uterine blood flow; avoid unless benefit outweighs risk. Second and third trimesters: Risk of uterine artery vasoconstriction and fetal hypoxia; prolonged use may cause neonatal hypotension, tachycardia, and irritability. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and uterine activity. Fetal heart rate monitoring via doppler or cardiotocography; assess for signs of fetal distress or reduced placental perfusion. |
| Fertility Effects | No known direct effects on fertility; however, potential for reduced uterine blood flow may impact implantation and early pregnancy viability. Use in women of reproductive age should be accompanied by pregnancy testing if indicated. |
| Clinical Pearls | VASOCON-A combines the vasoconstrictor naphazoline (0.025%) with the antihistamine pheniramine maleate (0.3%). Use with caution in patients with cardiovascular disease, hypertension, hyperthyroidism, or diabetes due to naphazoline's systemic sympathomimetic effects. Avoid use in patients with narrow-angle glaucoma. Prolonged use (>72 hours) may cause rebound congestion (rhinitis medicamentosa). For ocular use, limit to 3-4 days; for nasal use, limit to 3 days. Do not use in children under 6 years without medical supervision. |
| Patient Advice | Do not use for more than 3 days to avoid worsening congestion. · Avoid driving or operating machinery if dizziness or blurred vision occurs. · Do not share the bottle with others to prevent infection. · Remove contact lenses before using eye drops; wait 15 minutes before reinserting. · Do not use if solution changes color or becomes cloudy. · Keep bottle tightly closed when not in use. · For nasal spray, blow nose gently before use and avoid spraying into eyes. |